Roots Analysis has announced the addition of “Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017 - 2027” report to its list of offerings. The report provides an extensive study of the contract manufacturing market for biopharmaceuticals. It features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs.
Snehasish Das, the principal analyst, stated, “The development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited resources and finances to succeed by themselves. This has led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers”
One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. The report provides market’s projections, segmented on the basis of commonly outsourced business operations, types of expression systems and key geographical regions. Amongst other things, the study also covers the following:
Das further added, “Driven by increasing global demand and the rapidly expanding biopharmaceutical market, we expect the overall contract manufacturing market in the biopharmaceuticals domain to grow at an annualized rate of 8.7% between 2017 and 2027. The growth is likely to be higher in emerging markets of Asia and rest of the world.”
The report highlights the contributions of several players in the field, including the following:
It is also important to note that the trend for modular manufacturing is also increasing. The opinions and insights discussed in this report were influenced by valuable inputs from senior stakeholders in the industry. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies)
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market-2nd-edition-2017-2027/165.html or email sales@rootsanalysis.com
Contact:
Gaurav Chaudhary
+1-604-595-4954
gaurav.chaudhary@rootsanalysis.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES